• A
  • |
  • A
  • Text size

Overview: Current Management of Dyslipidemia in Adults

Access the full program.  This includes full newsletters, case studies, CME self-assessment and prescribing information.

The full newsletter Current management of dyslipidemia in adults, prescribing information and CME self-assessment are free for both AMA members and non-members.

Dyslipidemia, defined as any abnormality of serum lipids and lipoproteins, including low levels of HDL-cholesterol (HDL-C) that is associated with increased CHD risk, is a substantial contributor to the incidence of CHD. While national patient claims data from IMS Health show significant improvement in the percentage of patients diagnosed and treated for dyslipidemia over the past 4 years (49%, 2007; 41% 2011), a substantial number of patients diagnosed with dyslipidemia are still not being treated. Although new national guidelines from the National Cholesterol Education Program (NCEP) are in development (Spring 2012) the NCEP Adult Treatment Panel (ATP III) guidelines for the management of lipid and lipoprotein disorders for US adults, as revised in 2004, remain widely accepted both in the U.S. and internationally. This is due not only because they are supported by published clinical evidence, but also because they are relatively easy to apply in the clinical setting.

The current ATP III guidelines will be discussed and applied in the context of two representative cases that illustrate several familiar, as well as some less-appreciated aspects of the currently recommended management approach for the optimal treatment of dyslipidemia.

In "Current management of dyslipidemia in adults" physicians will learn to:

  • Apply the NCEP’s ATP III recommendations to patients at increased cardiovascular risk due to lipid derangements.
  • Stratify cardiovascular risk to guide treatment interventions.
  • Utilize evidence-based treatment intervention for dyslipidemia.

The full newsletter will provide you further insights into the use of currently available drugs (i.e., statins, statin combinations, resins, niacin, fibrates, cholesterol absorption inhibitors, and omega-3-fatty acid esters) used in the management of dyslipidemia.

View the full newsletter Current management of dyslipidemia in adults, and learn how to receive CME credit. Newsletters are available to all physicians, not just AMA members.